Interestingly, Viñuela-Berni et al. found a high percentage of CD14+, CD3+, and CD19+ in urine EVs of patients with active rheumatoid arthritis (Viñuela-Berni et al., 2015), which opened up the revenue for the use of urine EVs in the diagnosis of joint diseases. This evidence concerns the gene CD19 and arthropathy.